Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: A randomized, open-label, crossover study in taiwan

Clinical Therapeutics

Volumn 29, Issue 4, 2007, Pages 670-682

  Tsai, Yuh Shyan ^a,b   Lan, Shih Kai ^c   Ou, Jiann Hui ^a   Tzai, Tzong Shin ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c Buddhist Dhalin Tzu Chi General Hospital   (Taiwan)

Author keywords

crossover study; efficacy; generic drug; terazosin; therapeutic equivalence; tolerability

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIULCER AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; TERASIN; TERAZOSIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EPIDIDYMITIS; EYE DISEASE; FOLLOW UP; HUMAN; HYPOTENSION; INTERNATIONAL PROSTATE SYMPTOM SCALE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALAISE; MALE; MUSCULOSKELETAL DISEASE; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TAIWAN; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; UROFLOWMETRY; VITAL SIGN; XEROSTOMIA;

AGED; CROSS-OVER STUDIES; DIZZINESS; DRUGS, GENERIC; EDEMA; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; TAIWAN; THERAPEUTIC EQUIVALENCY;

EID: 34347353155     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.04.013     Document Type: Article

References (17)

1. (Suppl). Burnett A.L., and Wein A.J. Benign prostatic hyperplasia in primary care: What you need to know. J Urol. 175 (2006) S19-S24
2. Madersbacher S., Alivizatos G., Nordling J., et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 46 (2004) 547-554
3. De Mey C. Alphal-blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: What are the relevant differences in randomised controlled trials?. Eur Urol. 38 Suppl 1 (2000) 25-39
4. Roehrborn C.G., and Schwinn D.A. Alphaladrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 171 (2004) 1029-1035
5. Roehrborn C.G., Oesterling J.E., Auerbach S., et al., HYCAT Investigator Group. The Hytrin Community Assessment Trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 47 (1996) 159-168
6. Fabricius P.G., Weizert P., Dunzendorfer U., et al. Efficacy of once-aday terazosin in benign prostatic hyperplasia: A randomized, doubleblind placebo-controlled clinical trial. Prostate Suppl. 3 (1990) 85-93
7. Lepor H., Auerbach S., Puras-Baez A., et al. A randomized, placebocontrolled multicenter study of the efficacyand safety ofterazosin in the treatment of benign prostatic hyperplasia. J Urol. 148 (1992) 1467-1474
8. [published correction appears in Eur Urol. 1997;31:458]. Debruyne F.M., Witjes W.P., Fitzpatrick J., et al., ITT Group. The international terazosin trial: A multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur Urol. 30 (1996) 369-376
9. Boyarsky S., Jones G., Paulson D.F., and Prout Jr. G.R. A new look at bladder neck obstruction by the food and drug administration regulators: Guidelines for investigation of benign prostatic hypertrophy. Trans Amn Assoc Genitourin Surg. 68 (1976) 29-32
10. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int
11. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [WMA Web site]. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 (2006). http://www.wma.net/e/policy/63.htm Accessed November 15
12. [published correction appears in J Pharmacokinet Pharmacodyn. 2002;29:101]. Chow S.C., and Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 28 (2001) 155-169
13. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assess ing the equivalence of average bioavai lability. J Pharmacokinet Biopharm. 15 (1987) 657-680
14. Available at:. US Food and Drug Administration. Medical Dictionary for Regulatory Activities [MedDRA Web site]. Accessed November 15, (2006). http://www.meddramsso.com/MSSOWeb/index.htm
15. 1-adrenergic blockers in young men with primary bladder neck obstruction. J Urol. 168 (2002) 571-574
16. Chapple C.R. Alpha adrenoreceptor antagonists in the year 2000: Is there anything new?. Curr Opin Urol. 11 (2001) 9-16
17. Luzzi G.A., and O'Brien T.S. Acute epididymitis. BJU Int. 87 (2001) 747-755